About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 2NCT01305746

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

The purpose of this study is to evaluate the long-term safety of A-623 in subjects with SLE.

Lead sponsor: Anthera Pharmaceuticals•13 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Anthera Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Completed the treatment period specified in study AN-SLE3321 or were enrolled in study AN-SLE3321 prior to November 30, 2010

Exclusion Criteria

•Developed a new medical disease or condition that has made the subject unsuitable for this study in the opinion of the Investigator, including interference with written informed consent, study evaluation, completion, and/or procedures
•Pregnant or nursing
•Any prior administration of a B-cell modulating therapy other than A-623
•Received cyclophosphamide, cyclosporine, anti-TNF alpha therapies, transfusion, plasmapheresis or plasma exchange, IV immunoglobulin, or live vaccines according to listed wash-out periods

Related studies

RECRUITINGPhase 1

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)

NCT07371468 · Systemic Lupus Erythematosus

RECRUITINGEARLY Phase 1

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

NCT07617740 · REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS

RECRUITINGPhase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

NCT06308978 · Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM), and more

RECRUITINGPhase 2

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181 · Systemic Lupus Erythematosus

AGR+PNI as Predictors of Systemic Lupus Erythematosus Disease Activity

NCT07043153 · Systemic Lupus Erythematosus Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 13, 2014Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment382

Start dateApr 2011

Last updatedFeb 13, 2014

Condition

Systemic Lupus Erythematosus

Locations shown

Investigator Site 103

Birmingham, Alabama

Investigator Site 113

Long Beach, California

Investigator Site 110

Upland, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 13, 2014Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions